Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
MeiLan K. Han, Wen Ye, Di Wang, Emily White, Mehrdad Arjomandi, Igor Barjaktarević, Stacey-Ann Whittaker Brown, Russell G. Buhr, Alejandro P. Comellas, Christopher B. Cooper, Gerard J. Criner, Mark T. Dransfield, Frank Drescher, Rodney J. Folz, Nadia N. Hansel, Ravi Kalhan, Robert J. Kaner, Richard E. Kanner, Jerry A. Krishnan, Stephen C. Lazarus, Veeranna Maddipati, Fernando J. Martínez, Anne M. Mathews, Catherine A. Meldrum, Charlene McEvoy, Toru Nyunoya, Linda Rogers, William W. Stringer, Christine Wendt, Robert A. Wise, Stephen R. Wisniewski, Frank C. Sciurba, Prescott G. Woodruff
Abstract
BACKGROUND: Many persons with a history of smoking tobacco have clinically significant respiratory symptoms despite an absence of airflow obstruction as assessed by spirometry. They are often treated with medications for chronic obstructive pulmonary disease (COPD), but supporting evidence for this treatment is lacking. METHODS: ] to forced vital capacity [FVC] ≥0.70 and FVC ≥70% of the predicted value after bronchodilator use) to receive either indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) or placebo twice daily for 12 weeks. The primary outcome was at least a 4-point decrease (i.e., improvement) in the St. George's Respiratory Questionnaire (SGRQ) score (scores range from 0 to 100, with higher scores indicating worse health status) after 12 weeks without treatment failure (defined as an increase in lower respiratory symptoms treated with a long-acting inhaled bronchodilator, glucocorticoid, or antibiotic agent). RESULTS: was 2.48 percentage points (95% CI, 1.49 to 3.47) in the treatment group and -0.09 percentage points (95% CI, -1.06 to 0.89) in the placebo group, and the mean change in the inspiratory capacity was 0.12 liters (95% CI, 0.07 to 0.18) in the treatment group and 0.02 liters (95% CI, -0.03 to 0.08) in the placebo group. Four serious adverse events occurred in the treatment group, and 11 occurred in the placebo group; none were deemed potentially related to the treatment or placebo. CONCLUSIONS: Inhaled dual bronchodilator therapy did not decrease respiratory symptoms in symptomatic, tobacco-exposed persons with preserved lung function as assessed by spirometry. (Funded by the National Heart, Lung, and Blood Institute and others; RETHINC ClinicalTrials.gov number, NCT02867761.).